Here’s what you should know:
1. The treatment has shown localized target engagement in patients with moderate to severe ulcerative colitis.
2. TD-1473 is an orally administered treatment with the potential to treat several inflammatory intestinal diseases. The treatment differs from other available therapies because it acts at the site of inflammation on the intestinal wall with minimal systemic exposure.
3. Some early results include:
- Minimal systemic exposure
- No systemic immunosuppression or infections. Researchers reported no alterations in leukocytes, neutrophils or lymphocyte patients
- 70 percent of patients experienced greater than a one point reduction in Mayo bleeding subscores
- 30 percent of patients experienced greater than a one point reduction in Mayo endoscopic subscores
- 20 percent of patients demonstrated evidence of mucosal healing
4. Theravance will release top line results after the two remaining cohorts complete treatment. The company plans to advance to a larger induction and maintenance study in 2018.
More articles on gastroenterology:
GI leader to know: Dr. Christopher Kulisek of West Knox Gastroenterology
GI center to know: Lexington Clinic Gastroenterology
Stock market week-in-review for 5 large GI companies — July 31-Aug. 4
